Analytical Data
-
基因名
FLT3
-
简介
FLT3LG Proteinas, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. FLT3LG Protein, Human (HEK293) is the recombinant human-derived FLT3LG protein, expressed by HEK293, with tag free.
- Application
-
别名
Flt-3 Ligand; Flt3 ligand; FL; SL cytokine; Flt-3L
-
种属
Human
-
表达系统
HEK293
-
标签
Tag Free
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P49771-1
-
表达区间
T27-P185
-
分子量
24-30 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FLT3 (Fms-like tyrosine kinase 3) is a crucial receptor tyrosine kinase that plays a significant role in hematopoiesis and the development of various blood cells, particularly in the context of acute myeloid leukemia (AML). Mutations in the FLT3 gene, particularly the internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain, are prevalent in a substantial subset of AML cases and are associated with poor prognosis. Given its vital role in cell proliferation and survival, FLT3 has emerged as a key therapeutic target in cancer treatment. Researchers have been focusing on developing FLT3 inhibitors to improve clinical outcomes for AML patients. The study of recombinant FLT3 proteins facilitates a deeper understanding of FLT3's structure, function, and the mechanisms by which mutations lead to leukemogenesis. Additionally, recombinant FLT3 proteins are instrumental in the design of targeted therapies, biomarker development, and in vitro assays that help evaluate the efficacy of potential FLT3 inhibitors. Overall, the ongoing research into FLT3 and its recombinant proteins not only enhances our understanding of AML pathology but also accelerates the development of innovative treatments aimed at targeting FLT3-driven malignancies.
